Ceftolozanetazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

RCT (n=726) found high-dose ceftolozane –tazobactam was non-inferior to meropenem in terms of both 28-day all-cause mortality (24.0 vs. 25.3% died, respectively) and clinical cure at test of cure (54% vs 53%, respectively) for gram-negative nosocomial pneumonia in this population.

Source: Current Awareness Service for Health (CASH) - October 2, 2019 Category: Consumer Health News Source Type: news